163 related articles for article (PubMed ID: 36909923)
1. The "real-world" effectiveness and safety of omalizumab in patients with uncontrolled persistent allergic asthma in Slovakia: a subgroup analysis of the eXpeRience study.
Siracká S; Tinková LD; Hochmuth L; Leščišinová H; Hrubiško M; Dostálová K; Jeseňák M
Postepy Dermatol Alergol; 2023 Feb; 40(1):134-141. PubMed ID: 36909923
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic.
Kirchnerová OR; Valena T; Novosad J; Teřl M;
Postepy Dermatol Alergol; 2019 Feb; 36(1):34-43. PubMed ID: 30858777
[TBL] [Abstract][Full Text] [Related]
3. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.
Braunstahl GJ; Chen CW; Maykut R; Georgiou P; Peachey G; Bruce J
Respir Med; 2013 Aug; 107(8):1141-51. PubMed ID: 23721684
[TBL] [Abstract][Full Text] [Related]
4. Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma.
Pereira Barbosa M; Bugalho de Almeida A; Pereira C; Chen CW; Georgiou P; Peachey G;
Rev Port Pneumol (2006); 2015; 21(3):151-6. PubMed ID: 25926246
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients.
Arrobas A; Barbosa MP; Rabiais S; Vandewalle B; Félix J
Pulmonology; 2021; 27(2):124-133. PubMed ID: 32247710
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
Tarraf HN; Masoud HH; Zidan M; Wahba B
J Asthma; 2020 Feb; 57(2):160-166. PubMed ID: 30592242
[No Abstract] [Full Text] [Related]
7. Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting.
Braunstahl GJ; Chlumský J; Peachey G; Chen CW
Allergy Asthma Clin Immunol; 2013 Dec; 9(1):47. PubMed ID: 24305549
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
9. Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies.
Bousquet J; Humbert M; Gibson PG; Kostikas K; Jaumont X; Pfister P; Nissen F
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2702-2714. PubMed ID: 33486142
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland.
Sztafińska A; Gwardys M; Podlecka D; Mospinek E; Stelmach I
Postepy Dermatol Alergol; 2021 Jun; 38(3):427-432. PubMed ID: 34377123
[TBL] [Abstract][Full Text] [Related]
11. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
[TBL] [Abstract][Full Text] [Related]
12. Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study.
Al Ahmad M; Borboa Olivares LM; Cardoso AP; Djazmati W; Vinuesa MA; Domínguez MJG; Neto AC; Gamboa LU; Lee JK; Pinho N; Tassinari P
Open Respir Med J; 2022; 16():e187430642206130. PubMed ID: 37273950
[TBL] [Abstract][Full Text] [Related]
13. Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting.
Braunstahl GJ; Canvin J; Peachey G; Chen CW; Georgiou P
Biol Ther; 2014 Dec; 4(1-2):57-67. PubMed ID: 25371373
[TBL] [Abstract][Full Text] [Related]
14. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
[TBL] [Abstract][Full Text] [Related]
15. The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study.
Schreiber J; Schwab Sauerbeck I; Mailänder C
Adv Ther; 2020 Jan; 37(1):353-363. PubMed ID: 31741282
[TBL] [Abstract][Full Text] [Related]
16. 4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry.
Snelder SM; Weersink EJM; Braunstahl GJ
Allergy Asthma Clin Immunol; 2017; 13():34. PubMed ID: 28769983
[TBL] [Abstract][Full Text] [Related]
17. Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a
Li J; Wang C; Liu C; Kang J; Kong L; Huang Y; Liu S; Huang M; Wang L; Fogel R; Jaumont X; Yang J; Zhong N
World Allergy Organ J; 2020 Dec; 13(12):100469. PubMed ID: 34611470
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.
Corren J; Kavati A; Ortiz B; Colby JA; Ruiz K; Maiese BA; Cadarette SM; Panettieri RA
Allergy Asthma Proc; 2017 Jul; 38(4):250-263. PubMed ID: 28631599
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study.
Barnes N; Menzies-Gow A; Mansur AH; Spencer D; Percival F; Radwan A; Niven R
J Asthma; 2013 Jun; 50(5):529-36. PubMed ID: 23574000
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
